Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Prodromidou, A. Pandraklakis, C. Iavazzo (2020)The Emerging Role of Neutral Argon Plasma (PlasmaJet) in the Treatment of Advanced Stage Ovarian Cancer: A Systematic Review
Surgical Innovation, 27
H. Rehmani, Yue Li, Tao Li, Ravi Padia, Ozlem Calbay, Lingtao Jin, Huijun Chen, Shuang Huang (2020)Addiction to protein kinase Cɩ due to PRKCI gene amplification can be exploited for an aptamer-based targeted therapy in ovarian cancer
Signal Transduction and Targeted Therapy, 5
M. Muallem, Jumana Almuheimid, R. Richter, E. Braicu, S. Osman, J. Sehouli (2016)Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Anticancer research, 36 9
H. majd, F. Ferrari, S. Manek, K. Gubbala, R. Campanile, Kieran Hardern, R. Tozzi (2016)Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during Visceral-Peritoneal Debulking (VPD) in 100 consecutive patients with stage IIIC-IV ovarian cancer: A surgical-histological analysis.
Gynecologic oncology, 140 3
M. Baek, Shin-Wha Lee, J. Park, C. Rhim, Daeyeon Kim, D. Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, J. Nam (2016)Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy
International Journal of Gynecologic Cancer, 27
Figo Guidelines (2013)Staging classification for cancer of the ovary, fallopian tube, and peritoneum☆
S. Kim, Woo Hwang, Maria Lee, H. Kim, Kidong Kim, H. Chung, J. No, Jae-Weon Kim, Y. Kim, N. Park, Y. Song, D. Suh (2020)Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles
BMC Cancer, 20
R. Pounds, A. Phillips, S. Kehoe, J. Nevin, S. Sundar, A. Elattar, H. Teo, Kavita Singh, J. Bálega (2018)Diaphragm disease in advanced ovarian cancer: Predictability of pre-operative imaging and safety of surgical intervention.
European journal of obstetrics, gynecology, and reproductive biology, 226
M. Parsa (2015)Retroperitoneal Dissection of Ovarian Endometrioma Using J-Plasma Technology.
Journal of minimally invasive gynecology, 22 6S
N. Bacalbaşa, I. Bălescu, C. Bălălău, O. Ionescu, C. Stoica (2018)Association of Diaphragmatic Surgery as Part of Cytoreductive Effort in Advanced Stage Ovarian Cancer.
In vivo, 32 2
E. Panuccio, K. Leunen, E. Nieuwenhuysen, P. Neven, S. Lambrechts, I. Vergote (2016)Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer
International Journal of Gynecologic Cancer, 26
D. Dindo, N. Demartines, P. Clavien (2004)Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey
Annals of Surgery, 240
R. Siegel, K. Miller, A. Jemal (2019)Cancer statistics, 2019
CA: A Cancer Journal for Clinicians, 69
M. Oken, R. Creech, D. Tormey, J. Horton, T. Davis, E. McFadden, P. Carbone (1982)Toxicity and response criteria of the Eastern Cooperative Oncology Group
AMERICAN JOURNAL OF CLINICAL ONCOLOGY, 5
M. Liang, E. Prendergast, J. Staples, C. Holschneider, Joshua Cohen, I. Cass (2019)Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer
Journal of Surgical Oncology, 120
K. Lindemann, B. Gao, C. Mapagu, S. Fereday, C. Emmanuel, K. Alsop, N. Traficante, P. Harnett, D. Bowtell, A. deFazio (2018)Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
Gynecologic oncology, 150 2
Y. Sonoda, Narciso Olvera, D. Chi, C. Brown, N. Abu-Rustum, D. Levine (2010)Pathologic Analysis of Ex Vivo Plasma Energy Tumor Destruction in Patients With Ovarian or Peritoneal Cancer
International Journal of Gynecologic Cancer, 20
C. Grimm, P. Harter, F. Heitz, A. Bois (2015)The Sandwich Technique of Diaphragmatic Stripping or Full-Thickness Resection for Advanced Ovarian Cancer: How to Keep it Short and Simple
International Journal of Gynecologic Cancer, 25
J. Berek, C. Crum, M. Friedlander (2012)Cancer of the ovary, fallopian tube, and peritoneum
International Journal of Gynecology & Obstetrics, 119
F. Eggink, C. Koopmans, H. Nijman (2017)Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?
Current Opinion in Oncology, 29
R. Eskander, J. Kauderer, K. Tewari, R. Mannel, R. Bristow, D. O’Malley, S. Rubin, G. Glaser, C. Hamilton, K. Fujiwara, W. Huh, F. Ueland, J. Stephan, R. Burger (2018)Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
Gynecologic oncology, 149 3
S. Kehoe, E. Eisenhauer, D. Chi (2008)Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy.
Gynecologic oncology, 111 2 Suppl
M. Renaud, A. Sebastianelli (2013)Optimal cytoreduction with neutral argon plasma energy in selected patients with ovarian and primitive peritoneal cancer.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 35 1
Dimitris Tsolakidis, F. Amant, T. Gorp, K. Leunen, P. Neven, I. Vergote (2010)Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer.
Gynecologic oncology, 116 3
For the resection of diaphragmatic disease in patients with advanced ovarian cancer (OC), a plethora of ablative methods have been utilized. The present study aimed to present preliminary data on the use of J‑Plasma in OC with diaphragmatic involvement via a retrospective review of patients who had diaphragmatic stripping with of J‑Plasma<sup><sub>®</sub></sup> from January 2016 to September 2020. A total of 12 patients (median age, 65 years) were analyzed. Median operative time was 240 min while median estimated blood loss was 400 ml. Median operative time for diaphragmatic resection was 25 min. During a median follow‑up of 12 months, two recurrences were noted while none of the patients died of the disease. Median disease free survival was 12 months. Overall, the preliminary outcomes of the present study indicated that J‑Plasma could be safely used in diaphragmatic resection and it was associated with low rates of short‑term morbidity. However, further studies are warranted to reach to safe conclusions.
Molecular and Clinical Oncology – Spandidos Publications
Published: Jul 28, 2022
Access the full text.
Sign up today, get DeepDyve free for 14 days.